;PMID: 7864896
;source_file_1795.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..53] = [t:0..53]
;1)sentence:[e:59..201] = [t:59..201]
;2)section:[e:205..256] = [t:205..256]
;3)section:[e:260..365] = [t:260..365]
;4)sentence:[e:369..432] = [t:369..432]
;5)sentence:[e:433..569] = [t:433..569]
;6)sentence:[e:570..703] = [t:570..703]
;7)sentence:[e:704..952] = [t:704..952]
;8)sentence:[e:953..1088] = [t:953..1088]
;9)sentence:[e:1089..1320] = [t:1089..1320]
;10)section:[e:1324..1368] = [t:1324..1368]

;section 0 Span:0..53
;Biochem Biophys Res Commun. 1995 Feb 27;207(3):910-5.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..15] Biophys) (NNP:[16..19] Res)
        (NNP:[20..26] Commun) (,:[26..27] .) (CD:[28..32] 1995)
        (NNP:[33..36] Feb) (CD:[37..43] 27;207) (-LRB-:[43..44] -LRB-)
        (CD:[44..45] 3) (-RRB-:[45..46] -RRB-) (CD:[46..52] :910-5)
        (.:[52..53] .)))

;sentence 1 Span:59..201
;Mode of action and resistance to azole antifungals associated with the
;formation  of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.
;[92..109]:substance:"azole antifungals"
;[144..200]:substance:"14 alpha-methylergosta-8,24(28)-dien-3 beta,6
;alpha-diol"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[59..63] Mode))
      (PP (IN:[64..66] of)
        (NP (NN:[67..73] action))))
    (CC:[74..77] and)
    (NP
      (NP (NN:[78..88] resistance))
      (PP (TO:[89..91] to)
        (NP
          (NP (NN:[92..97] azole) (NNS:[98..109] antifungals))
          (VP (VBN:[110..120] associated)
            (NP (-NONE-:[120..120] *))
            (PP-CLR (IN:[121..125] with)
              (NP
                (NP (DT:[126..129] the) (NN:[130..139] formation))
                (PP (IN:[141..143] of)
                  (NP (CD:[144..146] 14)
                      (NN:[147..182] alpha-methylergosta-8,24-LRB-28-RRB--dien-3)
                      (NN:[183..189] beta,6) (NN:[190..200] alpha-diol)))))))))
    (.:[200..201] .)))

;section 2 Span:205..256
;Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE.
(SEC
  (FRAG (NNP:[205..210] Kelly) (NNP:[211..213] SL) (,:[213..214] ,)
        (NNP:[215..219] Lamb) (NNP:[220..222] DC) (,:[222..223] ,)
        (NNP:[224..230] Corran) (NNP:[231..233] AJ) (,:[233..234] ,)
        (NNP:[235..242] Baldwin) (NNP:[243..245] BC) (,:[245..246] ,)
        (NNP:[247..252] Kelly) (NNP:[253..256] DE.)))

;section 3 Span:260..365
;Krebs Institute for Biomolecular Research, Department of Molecular Biology, 
;University of Sheffield, UK.
(SEC
  (FRAG (NNP:[260..265] Krebs) (NNP:[266..275] Institute) (IN:[276..279] for)
        (NNP:[280..292] Biomolecular) (NNP:[293..301] Research) (,:[301..302] ,)
        (NNP:[303..313] Department) (IN:[314..316] of)
        (NNP:[317..326] Molecular) (NNP:[327..334] Biology) (,:[334..335] ,)
        (NNP:[337..347] University) (IN:[348..350] of)
        (NNP:[351..360] Sheffield) (,:[360..361] ,) (NNP:[362..365] UK.)))

;sentence 4 Span:369..432
;Azole antifungal compounds inhibit sterol 14 alpha-demethylase.
;[369..395]:substance:"Azole antifungal compounds"
;[404..431]:cyp450:"sterol 14 alpha-demethylase"
(SENT
  (S
    (NP-SBJ (NN:[369..374] Azole) (JJ:[375..385] antifungal)
            (NNS:[386..395] compounds))
    (VP (VBP:[396..403] inhibit)
      (NP (NN:[404..410] sterol) (CD:[411..413] 14)
          (NN:[414..431] alpha-demethylase)))
    (.:[431..432] .)))

;sentence 5 Span:433..569
;They are used  extensively for the treatment of immunocompromised patients
;where fungal  infection is common and often results in death.
(SENT
  (S
    (NP-SBJ-2 (PRP:[433..437] They))
    (VP (VBP:[438..441] are)
      (VP (VBN:[442..446] used)
        (NP-2 (-NONE-:[446..446] *))
        (ADVP (RB:[448..459] extensively))
        (PP (IN:[460..463] for)
          (NP
            (NP (DT:[464..467] the) (NN:[468..477] treatment))
            (PP (IN:[478..480] of)
              (NP
                (NP (JJ:[481..498] immunocompromised) (NNS:[499..507] patients))
                (SBAR
                  (WHADVP-1 (WRB:[508..513] where))
                  (S
                    (NP-SBJ (JJ:[514..520] fungal) (NN:[522..531] infection))
                    (VP
                      (VP (VBZ:[532..534] is)
                        (ADJP-PRD (JJ:[535..541] common)))
                      (CC:[542..545] and)
                      (VP
                        (ADVP (JJ:[546..551] often))
                        (VBZ:[552..559] results)
                        (PP-CLR (IN:[560..562] in)
                          (NP (NN:[563..568] death))))
                      (ADVP-1 (-NONE-:[568..568] *T*)))))))))))
    (.:[568..569] .)))

;sentence 6 Span:570..703
;Resistance to the compounds is  emerging, particularly in fungal pathogens
;obtained from AIDS patients  undergoing prolonged therapy.
;[588..597]:substance:"compounds"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[570..580] Resistance))
      (PP (TO:[581..583] to)
        (NP (DT:[584..587] the) (NNS:[588..597] compounds))))
    (VP (VBZ:[598..600] is)
      (VP (VBG:[602..610] emerging) (,:[610..611] ,)
        (PP-LOC
          (ADVP (RB:[612..624] particularly))
          (IN:[625..627] in)
          (NP
            (NP (JJ:[628..634] fungal) (NNS:[635..644] pathogens))
            (VP (VBN:[645..653] obtained)
              (NP (-NONE-:[653..653] *))
              (PP (IN:[654..658] from)
                (NP
                  (NP (NN:[659..663] AIDS) (NNS:[664..672] patients))
                  (VP (VBG:[674..684] undergoing)
                    (NP (VBN:[685..694] prolonged) (NN:[695..702] therapy))))))))))
    (.:[702..703] .)))

;sentence 7 Span:704..952
;We show here that cell growth arrest correlates  with the accumulation of 14
;alpha-methyl-ergosta-8,24(28)-dien-3 beta,6  alpha-diol in a yeast strain
;with a sterol 14 alpha-demethylase gene disruption,  which mimics stringent
;treatment conditions.
;[778..836]:substance:"14 alpha-methyl-ergosta-8,24(28)-dien-3 beta,6 
;alpha-diol"
;[862..889]:cyp450:"sterol 14 alpha-demethylase"
(SENT
  (S
    (NP-SBJ (PRP:[704..706] We))
    (VP (VBP:[707..711] show)
      (ADVP (RB:[712..716] here))
      (SBAR (IN:[717..721] that)
        (S
          (NP-SBJ
            (NML (NN:[722..726] cell) (NN:[727..733] growth))
            (NN:[734..740] arrest))
          (VP (VBZ:[741..751] correlates)
            (PP-CLR (IN:[753..757] with)
              (NP
                (NP (DT:[758..761] the) (NN:[762..774] accumulation))
                (PP (IN:[775..777] of)
                  (NP (CD:[778..780] 14)
                      (NN:[781..817] alpha-methyl-ergosta-8,24-LRB-28-RRB--dien-3)
                      (NN:[818..824] beta,6) (NN:[826..836] alpha-diol)))))
            (PP-LOC (IN:[837..839] in)
              (NP
                (NP
                  (NP (DT:[840..841] a) (NN:[842..847] yeast)
                      (NN:[848..854] strain))
                  (PP (IN:[855..859] with)
                    (NP (DT:[860..861] a)
                      (NML (NN:[862..868] sterol) (CD:[869..871] 14)
                           (NN:[872..889] alpha-demethylase))
                      (NN:[890..894] gene) (NN:[895..905] disruption))))
                (,:[905..906] ,)
                (SBAR
                  (WHNP-1 (WDT:[908..913] which))
                  (S
                    (NP-SBJ-1 (-NONE-:[913..913] *T*))
                    (VP (VBZ:[914..920] mimics)
                      (NP (JJ:[921..930] stringent) (NN:[931..940] treatment)
                          (NNS:[941..951] conditions)))))))))))
    (.:[951..952] .)))

;sentence 8 Span:953..1088
;Cells can overcome the effect of  such a block by a suppressor mutation in
;sterol delta 5,6 desaturation and  acquire azole resistance.
;[1028..1034]:substance:"sterol"
;[1071..1076]:substance:"azole"
(SENT
  (S
    (NP-SBJ (NNS:[953..958] Cells))
    (VP (MD:[959..962] can)
      (VP
        (VP (VB:[963..971] overcome)
          (NP
            (NP (DT:[972..975] the) (NN:[976..982] effect))
            (PP (IN:[983..985] of)
              (NP (JJ:[987..991] such) (DT:[992..993] a) (NN:[994..999] block))))
          (PP-MNR (IN:[1000..1002] by)
            (NP
              (NP (DT:[1003..1004] a) (NN:[1005..1015] suppressor)
                  (NN:[1016..1024] mutation))
              (PP-LOC (IN:[1025..1027] in)
                (NP
                  (NML (NN:[1028..1034] sterol) (SYM:[1035..1040] delta)
                       (CD:[1041..1044] 5,6))
                  (NN:[1045..1057] desaturation))))))
        (CC:[1058..1061] and)
        (VP (VB:[1063..1070] acquire)
          (NP (NN:[1071..1076] azole) (NN:[1077..1087] resistance)))))
    (.:[1087..1088] .)))

;sentence 9 Span:1089..1320
;Plasmid-based complementation of sterol 14  alpha-demethylase defect does not
;alter the azole susceptibility of strains  containing these suppressor
;mutations, showing resistance is due entirely to the  delta 5.6 desaturase
;defect.
;[1122..1150]:substance:"sterol 14  alpha-demethylase"
;[1177..1182]:substance:"azole"
;[1292..1312]:substance:"delta 5.6 desaturase"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP (NN:[1089..1096] Plasmid) (HYPH:[1096..1097] -)
              (VBN:[1097..1102] based))
        (NN:[1103..1118] complementation))
      (PP (IN:[1119..1121] of)
        (NP
          (NML (NN:[1122..1128] sterol) (CD:[1129..1131] 14)
               (NN:[1133..1150] alpha-demethylase))
          (NN:[1151..1157] defect))))
    (VP (VBZ:[1158..1162] does) (RB:[1163..1166] not)
      (VP (VB:[1167..1172] alter)
        (NP
          (NP (DT:[1173..1176] the) (NN:[1177..1182] azole)
              (NN:[1183..1197] susceptibility))
          (PP (IN:[1198..1200] of)
            (NP
              (NP (NNS:[1201..1208] strains))
              (VP (VBG:[1210..1220] containing)
                (NP (DT:[1221..1226] these) (NN:[1227..1237] suppressor)
                    (NNS:[1238..1247] mutations))))))
        (,:[1247..1248] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1248..1248] *))
          (VP (VBG:[1249..1256] showing)
            (SBAR (-NONE-:[1256..1256] 0)
              (S
                (NP-SBJ (NN:[1257..1267] resistance))
                (VP (VBZ:[1268..1270] is)
                  (ADJP-PRD (JJ:[1271..1274] due)
                    (ADVP (RB:[1275..1283] entirely))
                    (PP (TO:[1284..1286] to)
                      (NP (DT:[1287..1290] the)
                        (NML (SYM:[1292..1297] delta) (CD:[1298..1301] 5.6)
                             (NN:[1302..1312] desaturase))
                        (NN:[1313..1319] defect)))))))))))
    (.:[1319..1320] .)))

;section 10 Span:1324..1368
;PMID: 7864896 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1324..1328] PMID) (::[1328..1329] :) (CD:[1330..1337] 7864896)
        (NN:[1338..1339] -LSB-) (NNP:[1339..1345] PubMed) (::[1346..1347] -)
        (NN:[1348..1355] indexed) (IN:[1356..1359] for)
        (NNP:[1360..1368] MEDLINE-RSB-)))
